This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
![Opinion/decision on a Paediatric investigation plan (PIP): Vaxzevria (previously COVID-19 Vaccine AstraZeneca), COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Vaccines, PIP number: P/0273/2024](https://www.ema.europa.eu/sites/default/files/styles/oe_bootstrap_theme_medium_no_crop/public/2024-07/EMA_building_202407_v1-copyright-EMA.png?itok=NBYia_Eu)
Opinion/decision on a Paediatric investigation plan (PIP): Vaxzevria (previously...
Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharm...
Terrain Biosciences, backed by high-profile players in biotech, will design and ...
After Merck KGaA's recent confirmation that it's in discussions to acquire Sprin...
Antimicrobial Sales and Use (ASU) Platform: Release notes
After calling Rockville, Maryland, home for more than eight years, pharma giant ...
EMA Open Door Day, European Medicines Agency, Amsterdam, the Netherlands, from 9...
HMPC meeting report on European Union herbal monographs, guidelines and other ac...
After calling Rockville, Maryland home for more than eight years, pharma giant G...
Human medicines European public assessment report (EPAR): Duloxetine Viatris (pr...
Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir...
“Building a much better scientific enterprise means embracing the idea of collab...
Fears about corn, canola, and similar oils have taken root amid rising concerns ...
The settlement in U.S. v. Gilead could disturb the model of public-private partn...
Human medicines European public assessment report (EPAR): Pemetrexed Fresenius K...
Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,av...
Human medicines European public assessment report (EPAR): Pemetrexed Accord, pem...
Agenda - European medicines agencies network strategy (EMANS) to 2028 - webinar
Nilotinib product-specific bioequivalence guidance
Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg pro...
Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Myalepta, metreleptin,...